vancomycin + tobramycin + calcium sulfate

This refers to an investigational intramedullary calcium sulfate antibiotic depot being evaluated in a Phase 3 clinical trial (NCT05766670) sponsored by Wake Forest University Health Sciences. The treatment is designed to prevent fracture-related infections (FRI) in adult patients with severe (Type II or III) open tibia fractures. The depot consists of a biodegradable calcium sulfate carrier mixed with vancomycin and an aminoglycoside (typically tobramycin or gentamicin). During the definitive surgical fixation of the fracture with an intramedullary nail, the antibiotic-impregnated calcium sulfate is placed within the intramedullary canal. The calcium sulfate acts as a resorbable delivery system that provides high local concentrations of antibiotics directly at the injury site, targeting common pathogens such as *Staphylococcus aureus*. Unlike traditional non-resorbable carriers like PMMA beads, this depot is gradually absorbed by the body, eliminating the need for a secondary surgical procedure for removal.

Other names

Intramedullary Calcium Sulfate Antibiotic DepotLocal Antibiotic DepotCalcium Sulfate Antibiotic Depot